

Lupin launches Ceftriaxone vials in the US market

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------------	-------------------	-------------------------	--------------------------

Mumbai, July 21, 2005: Lupin Ltd announced that it has launched **Ceftriaxone** vials for injection in the US market. Ceftriaxone is the generic equivalent of Rocephin[®] marketed by Roche. As per MAT May 2005 IMS data, the U.S. market size for Ceftriaxone was at \$ 756 million.

Earlier in October 2003, Lupin had received the ANDA approval from the U.S. Food and Drug Administration (USFDA) for 250 mg, 500 mg, 1g and 2g variants of Ceftriaxone vials for injection. The launch follows the expiry of the product patent on July 19, 2005.

The company has entered into an agreement with **Baxter** Healthcare Corporation, a leading global medical products company headquartered in the United States, whereby Baxter will exclusively distribute the company's generic version of Ceftriaxone vials in the U.S. hospital market.

Lupin has also entered into a separate agreement with **Henry Schein**, Inc. whereby Henry Schein will exclusively distribute the product to physician offices. Henry Schein, a Fortune 500[®] company, is a leading distributor to physician practices.

Lupin's Chairman Dr. Desh Bandhu Gupta said, "The launch of Ceftriaxone in the US marks a major milestone for Lupin's advanced markets strategy. This product significantly enhances our presence in the US generic market. We believe that our ability to manufacture this product combined with the fact that there are a limited number of players in this market will help in creating strong value for Lupin's shareholders."

A complex, high technology cephalosporin antibiotic, ceftriaxone injection is used to treat infections of the urinary tract, lower respiratory tract, meningitis, skin and skin structure, surgical prophylaxis, intra-abdominal infections and pelvic inflammatory disease.

NB: Rocephin[®] is a registered trademark of Roche.

About Lupin

Headquartered in Mumbai, Lupin (<http://www.lupinworld.com>) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the USFDA and two facilities have been approved by the UKMHRA